{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:41:39Z","timestamp":1772134899462,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41409-024-02214-5","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:02:33Z","timestamp":1709647353000},"page":"824-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia"],"prefix":"10.1038","volume":"59","author":[{"given":"Qianwen","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Suo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenhua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-1081","authenticated-orcid":false,"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-6260","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2214_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2214_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29\u201341.","journal-title":"Blood"},{"key":"2214_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","volume":"28","author":"K Tarlock","year":"2022","unstructured":"Tarlock K, Sulis ML, Chewning JH, Pollard JA, Cooper T, Gamis A, et al. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transpl Cell Ther. 2022;28:530\u201345.","journal-title":"Transpl Cell Ther"},{"key":"2214_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909\u201318.","journal-title":"N Engl J Med"},{"key":"2214_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2214_CR6","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121:2734\u20138.","journal-title":"Blood"},{"key":"2214_CR7","first-page":"2145","volume":"117","author":"FPS Santos","year":"2011","unstructured":"Santos FPS, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, et al. Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia. Cancer-Am Cancer Soc. 2011;117:2145\u201355.","journal-title":"Cancer-Am Cancer Soc"},{"key":"2214_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28979","volume":"68","author":"G Egan","year":"2021","unstructured":"Egan G, Chopra Y, Mourad S, Chiang KY, Hitzler J. Treatment of acute myeloid leukemia in children: A practical perspective. Pediatr Blood Cancer. 2021;68:e28979.","journal-title":"Pediatr Blood Cancer"},{"key":"2214_CR9","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1182\/blood-2011-05-353185","volume":"118","author":"A Staffas","year":"2011","unstructured":"Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118:5905\u201313.","journal-title":"Blood"},{"key":"2214_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/leu.2016.177","volume":"31","author":"E Manara","year":"2017","unstructured":"Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017;31:18\u201325.","journal-title":"Leukemia"},{"key":"2214_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.","journal-title":"J Hematol Oncol"},{"key":"2214_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/cac2.12014","volume":"40","author":"FM Zheng","year":"2020","unstructured":"Zheng FM, Zhang X, Li CF, Cheng YF, Gao L, He YL, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. Cancer Commun. 2020;40:93\u2013104.","journal-title":"Cancer Commun"},{"key":"2214_CR13","unstructured":"Stem Cell Application Group CSoHCMA. [Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III) -acute graft-versus-host disease (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41:529\u201336."},{"key":"2214_CR14","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2214_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401 e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2214_CR16","unstructured":"Hematopoietic Stem Cell Application Group CSoHCMA, China Association for the Prevention of Hematology D. [Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021;42:265\u201375."},{"key":"2214_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00277-018-3265-1","volume":"97","author":"X Zhao","year":"2018","unstructured":"Zhao X, Wang Z, Ruan G, Liu Y, Wang Y, Zhang X, et al. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol. 2018;97:967\u201375.","journal-title":"Ann Hematol"},{"key":"2214_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07043-5","volume":"20","author":"GH Hu","year":"2020","unstructured":"Hu GH, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, et al. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer. 2020;20:553.","journal-title":"BMC Cancer"},{"key":"2214_CR19","unstructured":"Stem Cell Application Group CSoHCMA, Chinese Pediatric Society CMA. [Chinese expert consensus of the allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia (not APL) (2022)]. Zhonghua Xue Ye Xue Za Zhi. 2022;43:802\u20139."},{"key":"2214_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","volume":"7","author":"YR Lai","year":"2014","unstructured":"Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59.","journal-title":"J Hematol Oncol"},{"key":"2214_CR21","first-page":"291","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without. T-cell Deplet Treat hematological malignancies Bone Marrow Transpl. 2006;38:291\u20137.","journal-title":"T-cell Deplet Treat hematological malignancies Bone Marrow Transpl"},{"key":"2214_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2018.11.020","volume":"25","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease-Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial. Biol Blood Marrow Transpl. 2019;25:529\u201337.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2214_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","volume":"22","author":"B Oran","year":"2016","unstructured":"Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, et al. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transpl. 2016;22:1218\u201326.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2214_CR24","first-page":"6110","volume":"118","author":"J How","year":"2012","unstructured":"How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer-Am Cancer Soc. 2012;118:6110\u20137.","journal-title":"Cancer-Am Cancer Soc"},{"key":"2214_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00277-015-2580-z","volume":"95","author":"JS Ahn","year":"2016","unstructured":"Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, et al. Transplant outcomes of the triple-negative NPM1\/FLT3-ITD\/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. Ann Hematol. 2016;95:625\u201335.","journal-title":"Ann Hematol"},{"key":"2214_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/CCO.0b013e32835ec91f","volume":"25","author":"S Brunet","year":"2013","unstructured":"Brunet S, Martino R, Sierra J. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3\/ITD). Curr Opin Oncol. 2013;25:195\u2013204.","journal-title":"Curr Opin Oncol"},{"key":"2214_CR27","first-page":"3005","volume":"122","author":"A Deol","year":"2016","unstructured":"Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer-Am Cancer Soc. 2016;122:3005\u201314.","journal-title":"Cancer-Am Cancer Soc"},{"key":"2214_CR28","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2015-06-651562","volume":"126","author":"C Schmid","year":"2015","unstructured":"Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126:2062\u20139.","journal-title":"Blood"},{"key":"2214_CR29","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","volume":"108","author":"S Meshinchi","year":"2006","unstructured":"Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654\u201361.","journal-title":"Blood"},{"key":"2214_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/ajh.25082","volume":"93","author":"J Canaani","year":"2018","unstructured":"Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:736\u201344.","journal-title":"Am J Hematol"},{"key":"2214_CR31","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00277-020-04026-1","volume":"99","author":"G Helbig","year":"2020","unstructured":"Helbig G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, Kopinska A, Boral K, et al. Pre-transplant FLT3\/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Ann Hematol. 2020;99:1845\u201353.","journal-title":"Ann Hematol"},{"key":"2214_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865\u201373.","journal-title":"Haematologica"},{"key":"2214_CR33","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cam4.4218","volume":"11","author":"R Al Hamed","year":"2022","unstructured":"Al Hamed R, Labopin M, Daguindau E, Niittyvuopio R, Huynh A, Socie G, et al. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. Cancer Med. 2022;11:1068\u201380.","journal-title":"Cancer Med"},{"key":"2214_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00277-015-2383-2","volume":"94","author":"J Schweitzer","year":"2015","unstructured":"Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, et al. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Ann Hematol. 2015;94:1327\u201336.","journal-title":"Ann Hematol"},{"key":"2214_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"2214_CR36","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327\u201337.","journal-title":"Clin Cancer Res"},{"key":"2214_CR37","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38:2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"2214_CR38","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan ZP, Xu YJ, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201\u201312.","journal-title":"Lancet Oncol"},{"key":"2214_CR39","doi-asserted-by":"publisher","unstructured":"Shang QH, Bi L, Cheng YF, Suo P, Hu GH, Huang XJ, et al. data. figshare. Dataset. 2024. https:\/\/doi.org\/10.6084\/m9.figshare.24417739.","DOI":"10.6084\/m9.figshare.24417739"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02214-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:06:02Z","timestamp":1717729562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02214-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2214"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02214-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3477326\/v1","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}